Get to know our clinical trials
A reduced dose of thrombolytic therapy for patients with intermediate-high risk acute pulmonary embolism: randomized controlled trial.
THE AIM OF THIS STUDY IS TO DETERMINE THE EFFICACY OF A REDUCED DOSE OF THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM. THE EFFICACY OF THIS TREATMENT IS EVALUATED 30 DAYS AFTER PULMONARY EMBOLISM.
Status
In recruitment
headquarters
Madrid
Technical Summary
- A REDUCED DOSE OF THROMBOLYTIC THERAPY FOR PATIENTS WITH INTERMEDIATE-HIGH RISK ACUTE PULMONARY EMBOLISM: RANDOMIZED CONTROLLED TRIAL.
- Code EudraCT: 2018-000816-96
- Protocol number: P160924
- Promoter: Sociedad Española de Oncología Médica (SEOM)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.